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ABSTRACT 
The objective of our investigation was to formulate a self-emulsifying drug delivery system (SEDDS) of Silymarin using minimum surfactant 
concentration that could include its solubility, stability and also oral bioavailability. Silymarin are widely use drug for the treatment of hepatitis 
C virus, have poor bioavailability due to their poor water solubility that limits dissolution rate. To overcome this limitation SEDDS were 
prepared to attempt their release property. The solubility of the drug was determined by various vehicles. Ternary phase diagram was 
constructed using Cinnamon (oil), Tween 20 (surfactant) and PEG 200 (co-surfactant) and water to identify the efficient Self-emulsifying 
region. Through pseudo ternary phase diagram investigation, four different formulations were prepared of liquid-solid SEDDS. The stability can 
be achieved more by developing the solid dosage form by converting the liquid SEDDS to solid SEDDS formulation. The liquid SEDDS was 
converted into free flowing powder by adsorption of liquid onto solid carriers by using Aerosil 200 that provides a high surface area. The in 
vitro release of solid SEDDS was 58.16% within 8 h. The optimized formulation (F1) showed higher dissolution release than the commercial 
product.  The in vitro drug release kinetics study of optimized formula was found better Regression coefficient (R2) compare with other 
formulation. In conclusion the study elucidated that adsorption to solid carrier technique could be useful method to prepare the solid SEDDS 
from liquid SEDDS, which can improve oral absorption of Silymain.   
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INTRODUCTION 
Self-emulsifying drug delivery systems are also known as 
SEDDS. The need for increased folds in bioavailability of oral 
lipophilic drugs which led to studies on self-emulsifying drug 
delivery system. Drugs which have low solubility in aqueous 
medium but high permeability have given rise to self-
emulsifying drug delivery systems or we can say as SEDDS 
are used to solve low bioavailability issues of poorly soluble 
& highly permeable compounds.1 Self-emulsifying drug 
delivery systems (SEDDS) are mixtures of oils and 
surfactants, ideally isotropic, and sometimes containing co-
solvents, which emulsify spontaneously to produce fine oil-
in-water emulsions (o/w) when introduced into aqueous 
phase under gentle agitation. 1,2. The first marketed SEDDS is 
cyclosporine and it was found to have higher bioavailability 
than the conventional drug.3 Emulsions are liquid dosage 
forms which consist of two immiscible phases; where one is 
a dispersed phase is dispersed into the other phase, 
dispersion medium, and stability is maintained with the help 
of an emulsifying agent. The process of self-emulsification 
can be better explained with the ouzo effect which occurs in 
anise-flavoured liquors where an oil-in-water emulsion is 
formed when the anise comes in contact with water.3 
When SEDDS formulation is released in the lumen of the 
gastrointestinal tract, they come in contact with GI fluid and 
form a fine emulsion (micro/ Nano) So called as in situ 
emulsification or self-emulsification which further leads to 
solubilisation of drug that can subsequently be absorbed by 
lymphatic pathways, bypassing the hepatic first-pass effect. 1, 
2 Recently, SEDDS have been formulated using medium chain 
tri-glyceride oils and non-ionic surfactants, the latter being 
less toxic. Upon per oral administration, these systems form 
fine emulsions (or micro-emulsions) in gastro-intestinal tract 
(GIT) with mild agitation provided by gastric mobility.2 
The better absorbed drugs across the gastrointestinal tract 
(GIT) provide good oral bioavailability but have number of 
potentially limiting factors. These include appropriate 
stability and solubility in the GI fluid, reasonable intestinal 
permeability, and resistance to metabolism both within the 
enterocyte and the liver. 4 
Silymarin is a mixture of flavonoids extracted from seeds of 
the MILK THISTLE, Silybum marianum. It consists primarily 
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of silybin and its isomers, silicristin and silidianin. Silymarin 
displays antioxidant and membrane stabilizing activity. It 
protects various tissues and organs against chemical injury, 
and shows potential as an antihepatoxic agent. Silymarin is 
widely used to treat liver disease and it can shows 
hepatoprotective activity. It is also used to treat Amanita 
mushroom poisoning, hepatitis, alcoholic liver disease and 
cirrhosis, hypercholesterolemia, psoriasis etc.5 
 
Figure 1: Structure of Silymarin 
MATERIALS & METHODS 
Materials  
Silymarin obtained as gift sample from Sigma Aldrich, India. 
Cinnamon oil purchased from Yarrow Chem Products 
(Mumbai), Tween 20 and PEG-200 purchased from qualigens 
Fine Chemicals (Mumbai) respectively. 
Methodology 
I. Preparation of liquid Self-Emulsifying Drug 
Delivery System of Silymarin  
Based on the result of solubility study and Pseudo ternary 
phase diagram the appropriate quantities of oil phase, 
surfactant and co-surfactant were elected.  Required quantity 
of Silymarin dispersed in appropriate quantity of co-
surfactant in a beaker in the presence of heat by using 
magnetic stirrer. Accurately weighed quantity of oil was 
blended with the surfactant in another beaker. The blends 
were mixed thoroughly by using magnetic stirrer. This (drug 
+ co-surfactant) mixture was added slowly with another 
mixture (oil + surfactant). At last, total mixture were mixed 
properly  to get homogenized formulation.6 
II. Prepared Solid Self-emulsifying drug delivery 
system 
The solid SEDDS was prepared by adsorption method. 
Accurate quantity of Aerosil 200, MCC and Lactose were 
mixed with the liquid SEDDS where Aerosil 200 acts as a 
adsorbing agent in a small mortar and pestle. The resulting 
formulation was uniformly homogenized to ensure that the 
mixture was uniformly distributed. The damp mass was 
passed through sieve No. 120 and dried at room 
temperature.6,7
 
Table 1: Various Formulations of Silymarin SEDDS 
Formulation Code Drug (mg) Amount of Oil (%) Ratio of S/CoS  
F1 140 5 1:1 
F2 140 10 1:1 
F3 140 15 1:1 
F4 140 20 1:1 
 
RESULT AND DISCUSSION 
Standard curve of Silymarin in Acidic Buffer pH 1.2 
Standard curve of Silymarin was successfully obtained in 
acidic buffer 1.2 by measuring the absorbance with respect 
to concentration at the λ max of 286 nm of Silymarin and 
linear regression coefficient is 0.9996.8 
Table 2: Calibration curve of Silymarin in pH 1.2 
Concentration (μg/ml) Absorbance (nm) 
5 0.151 
10 0.315 
15 0.477 
20 0.625 
25 0.798 
 
 
Figure 2: Standard curve of Silymarin in Acidic Buffer pH 
1.2 
 
Standard curve of Silymarin in phosphate buffer 7.4 
Standard curve of Silymarin was successfully obtained in 
phosphate buffer 7.4 by measuring the absorbance with 
respect to concentrations at the λ max of 286 nm of 
Silymarin and linear regression coefficient is 0.9999.9 
Table 3: Absorbance of Silymarin in Phosphate buffer 
pH 7.4 at λmax 286 nm 
Concentration (μg/ml) Absorbance (nm) 
5 0.108 
10 0.21 
15 0.311 
20 0.408 
25 0.514 
 
 
Figure 3: Standard curve of Silymarin in phosphate 
buffer 7.4 
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Solubility Study 
Solubility study of Silymarin in various oil, surfactant and co-
surfactant were determined.  Fig. 4 showed the Silymarin is 
better soluble in Cinnamon oil and Soyabean oil compared to 
other. Fig. 5 showed the Silymarin was better soluble in 
Tween 20 and Span 80 compared to other surfactants. Fig. 6 
showed the Silymarin was better soluble in PEG 200, PEG 
400 compared to other co-surfactants.10 
 
 
Figure 4: Solubility of Silymarin in various Oils 
 
Figure 5: Solubility of Silymarin in various Surfactants 
 
Figure 6: Solubility of Silymarin in various Co-surfactants 
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Pseudo ternary Phase diagram 
Ternary phase diagrams were constructed to identify the 
self-emulsifying regions and also to establish the optimum 
concentrations of oil, surfactant and co-surfactant. In the 
phase diagrams, Cinnamon oil, Tween 20 and PEG 200 were 
constructed as oil, surfactant and co-surfactant respectively, 
with different ratios of surfactant and co-surfactant (Smix). 
From the diagrams the surfactant and co-surfactant mixture 
(Smix) ratio 1:1 showed better self-emulsification region 
than the other ratio 1:2, 1:3.10,11,12 
 
 
Figure 7: 1:1 ratio                                                                     Figure 8: 1:2 ration 
 
 
Figure 9:  1:3 ratio 
 
FTIR study 
Drug excipient interaction was checked by comparing the IR spectra. The functional groups of pure drug remained intact in 
physical mixture containing different excipient.13 
 
Figure 10: FTIR of Silymarin 
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Figure 11: FTIR of Cinnamon oil + Silymarin 
 
Figure 12: FTIR of Silymarin: Cinnamon oil: Tween 20: PEG 200 (1:0.5:1:1) 
 
Evaluation of Liquid Self Emulsifying Drug Delivery 
System 
A. Thermodynamic Stability Study 
Centrifugation study 
By using laboratory centrifuge (REMI R-8C) at 5000 rpm the 
formulation were centrifuged for 30 min. 
Heating and cooling cycle 
Three heating/cooling cycles between 4ºC and 40ºC with 
storage at each temperature for not less than 24 h. 
Freeze thaw cycle 
Formulations were subjected to 3 freeze-thaw cycles, which 
included freezing at -4ºC for 24 h followed by thawing at 
40ºC for 24 h. Centrifugation was performed at 3000 rpm for 
5 min. The formulations were then observed for phase 
separation. 
B. Self-Emulsification Time 
The efficiency of self-emulsification was checked using 
dissolution apparatus. One ml formulation was dissolved in 
250 ml of water at 37±0.5ºC. At 60 rpm gentle agitation was 
provided by paddle rotating. 
C. Dispersibility Test 
The efficiency of self-emulsification of oral nano or micro 
emulsion is assessed by standard USP type II dissolution 
apparatus. 1 ml of each formulation was dissolved in 500 ml 
of water at 37 ± 1ºC. A standard stainless steel dissolution 
paddle was used with rotating speed of 50 rpm to provide 
gentle agitation. 
 
 
Table 4: Results of thermodynamic stability of emulsion, emulsification time, and dispersibility test of liquid self-
emulsifying drug delivery system. 
Formulation No 
Thermodynamic Stability  
Emulsification 
Time (Second) 
Dispersibility 
Test (Grade) 
Centrifugation 
study 
Heating and 
Cooling cycle 
Freeze Thaw 
Cycle 
F1 Yes Yes Yes 51 A 
F2 Yes Yes Yes 57 A 
F3 Yes Yes Yes 67 A 
F4 Yes Yes Yes 64 A 
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Evaluation of Solid Self Emulsifying Drug Delivery 
System 
I. Micromeritic Properties Study 
a. Bulk Density 
Bulk density of the powder is the ratio of the mass of an 
unstrapped powder sample and its volume including the 
contribution of the interparticulate void volume. 
The bulk density was determined by following equation- 
Bulk Density (ρb) =  
b. Tapped Density 
The tapped density was obtained by mechanically tapping a 
graduated measuring cylinder or vessel containing the 
powder blend. 
The trapped density was determined by following equation- 
Tapped Density (ρt) =  
c. Hausner’s Ratio  
The hausner’s ratio was calculated by this following formula- 
Hausner’s Ratio (H) =  
d. Carr’s Index 
Carr’s Index was determined by following equation 
Carr’s Index (C) =  X 100 
e. Angle of Repose 
Angle of repose was determined by Fixed Funnel method. 
Angle of repose was determined by following equation- 
tanθ = h/r 
or θ = tan-1 (h/r), 
θ = Angle of repose, h = Height of pile of powder blend, r 
= Radius of heap.
 
Table 5: Results of micromeritic properties of solid self-emulsifying drug delivery system 
Formulation 
No 
Bulk Density 
(ρb) 
(gm/cm3) 
Tapped 
Density (ρt) 
(gm/cm3) 
Carr’s Index 
(C) 
Hausner’s 
Ratio (H) 
Angle of 
Repose (θ) 
F1 0.391 0.498 21.485 1.273 23.728 
F2 0.303 0.515 41.165 1.7009 33.398 
F3 0.354 0.485 27.010 1.372 30.618 
F4 0.413 0.529 21.92 1.280 35.417 
 
II. Drug Content Determination 
Silymarin loaded solid SEDDS (10 mg) was dissolved in 100 
ml of methanol in 100 ml volumetric flask. Filtered the 
solution through whatman filter paper. Then diluted the 
solution with methanol. Then the solution was analyzed by 
UV spectrophotometer.14 
III. In-vitro release studies 
The percent cumulative release of Silymarin from the 
formulations F1 was found to be higher than the other 
formulations and marketed product (Silymarin®). The 
cumulative percentage drug released after 8 hours for F1and 
marketed product was 58.16% and 57.26% respectively. 
Cumulative percent drug release is high in formulation F1 
because of the amount of oil present in the formulation was 
lower than the other formulation.  
 
Table 6: Results of Drug content of solid self-emulsifying 
drug delivery system 
Formulation No Drug Content (%) 
F1 98.57 
F2 90.78 
F3 89.94 
F4 95.62 
 
 
Table 7: In vitro drug release data comparison study between formulations (F1-F4), Crude drug and Marketed product. 
Time (h) F1 F2 F3 F4 Crude drug 
Marketed 
product 
1 12.3437 11.8932 10.9021 9.6407 5.8565 11.9833 
2 22.0882 18.6639 21.5460 17.2198 12.8908 21.7274 
3 25.4327 26.3299 25.4321 22.7243 14.8808 25.7026 
4 29.3107 31.4741 30.4520 26.6047 15.9642 30.5335 
5 35.3517 36.2551 34.4520 33.1863 17.4971 35.5335 
6 41.5753 43.4684 40.0426 37.0679 18.1295 40.3141 
7 45.7268 48.7923 47.5271 43.4693 18.4906 48.5185 
8 58.1652 54.5646 51.4998 48.1616 24.3475 57.2673 
 
Mantry et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):54-61 
ISSN: 2250-1177                                                                                  [60]                                                                                 CODEN (USA): JDDTAO 
 
Figure 13: In vitro drug release profile comparison study between formulations (F1-F4), Crude drug and Marketed 
product. 
Drug Release Kinetics Study of Formulation (F1-F4) 
For the determination of the drug release kinetics, the in 
vitro data was analyzed by zero order, first order, Higuchi 
and Krosemeyer Peppas equation for each formulation. The 
optimized formulation was found to be F1 in release kinetics 
study also because it shows the maximum % cumulative 
drug release from the formulation after 8hrs. 
 
Table 8: Drug release kinetics studies (Regression coefficient (r2)) of prepared  
FORMU 
LATION 
CODE 
ZERO 
(r2) 
FIRST 
(r2) 
HIGUCHI 
(r2) 
HIXON 
CROWELL 
(r2) 
KORSMEYER 
PEPPAS 
(r2) 
F1 0.9171 0.6541 0.9447 0.966 0.9768 
F2 0.9972 0.9328 0.9878 0.9666 0.9976 
F3 0.9743 0.6555 0.9698 0.6845 0.9856 
F4 0.9876 0.6916 0.9617 0.7114 0.9971 
 
 
Figure 14: Zero order kinetics of optimized formulation 
F1 
 
Figure 15: First order kinetics of optimized formulation 
F1 
 
Figure 16: Krosmeyer Paper Model of optimized 
formulation F1 
 
Figure 17: Higuchi Model of optimized formulation F1 
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Figure 18: Hixon crowell model of optimized 
formulation F1 
CONCLUSION 
The aim of present study was to formulate and evaluate 
liquid-solid self emulsifying drug delivery system of poorly 
water soluble drug Silymarin. And four formulations was 
prepared by using different ratio of cinnamon oil as oil phase 
and Tween 20 and PEG 200 as surfactant and co-surfactant 
respectively. In this present study pre-formulation 
parameters were investigated. The calibration curve of 
Silymarin in Phosphate buffer 7.4 and acidic buffer 1.2 were 
determined and the regression co-efficient were 0.9999 and 
0.9996 respectively. The solubility study was conducted and 
from that Silymarin was soluble in Cinnamon oil, Soyabeen 
oil used as oil, Tween 20, Span 80 used as a surfactant and 
PEG 200, PEG 400 used as a co-surfactant. They showed 
better result compared to other substances.  From pseudo 
ternary phase diagram the surfactant and co-surfactant 
mixture (Smix) ratio 1:1 showed better self-emulsifying 
region than 1:2, 1:3. Through pseudo ternary phase diagram 
investigation, four different formulations were prepared of 
liquid-solid SEDDS. The conclusion was F1 formulation 
confirmed better result than the other three formulations, 
the value of angle of repose less than 25 and the drug content 
98.57% showed in F1 formulation. The drug release from F1 
formulation and marketed product was 58.16% and 57.26% 
respectively after 8 h. Thus F1 formulation showed higher 
drug release from marketed product. So the BCS Class II drug 
Silymarin loaded SEDDS showed promising result of 
increased absorption and increased oral bioavailability from 
the marketed formulation.   
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